Alpinuity Bio was founded on a simple observation: the most valuable scientific support is not advice delivered from the outside — it is collaboration delivered from within.
We work alongside your team — not as external reviewers producing reports, but as embedded scientific partners who understand the pressures, timelines, and decisions your project faces in real time.
This means we are available when you need to think through a data readout at 6pm on a Friday. It means we push back when we think the data is being interpreted too optimistically. And it means we bring the same critical objectivity to your project that we would expect from a trusted colleague — because that is what we aim to be.
The name reflects two things we care about: altitude (the Alpine in Alpinuity — the clarity and perspective that comes from looking at the full landscape) and continuity (staying with you from discovery through to clinical development, not just for a defined engagement).
We are based in Germany and work with biotech and pharma clients across Europe and internationally.
Peter is a biomarker and translational science expert with more than 15 years of experience across discovery, preclinical and clinical phases of drug development. He has worked with both large pharmaceutical organisations and small biotech companies, and understands the different pressures that apply at each scale.
His expertise spans biomarker strategy and development, translational medicine, precision medicine programme design, and scientific advisory board support.
Peter writes weekly on biomarker strategy, clinical translation, and precision medicine — perspectives shaped by years of working at the boundary between what discovery delivers and what clinical development requires.
Schedule a call to discuss your discovery project and build an objective, data-driven path to the clinic.
Book a free consultation